Supplies of Esperavir® (molnupiravir) have started to the healthcare system, including pharmacies

Promomed 10 February 2022

Promomed Group begun supplying a new drug for the treatment of coronavirus infection based on the molnupiravir molecule. The first batch of Esperavir®, the drug approved last week, was shipped today from the Biokhimik plant (member of the Promomed Group) for the Moscow Department of Health, the Ministry of Health of the Republic of Mordovia, and for distributors and pharmacy chains.

«We consider it critical to make the most advanced coronavirus therapy in the world available to our compatriots as quickly as possible. The first anti-covid drug based on the internationally recognized molecule molnupiravir was approved abroad in December 2021, and already in February, the domestic drug developed by Promomed Group based on the same molecule using original technology became available for the national healthcare system. Today, our plant in Saransk is operating at full capacity to meet the needs of all regions,» said Maxim Smagin, CEO of Promomed Group.

The drug is available in capsules of 200 and 400 mg and is indicated for the treatment of mild to moderate coronavirus infection on an outpatient basis.

«The evidence base for molnupiravir includes data from clinical studies involving more than 3,000 patients from around the world with varying degrees of severity of COVID-19, including patients of an older age group or those with comorbid conditions. Esperavir has passed all stages of clinical testing and demonstrated high efficacy in terms of reducing the risk of hospitalization and patient condition worsening, the rate of virus elimination, and the time until clinical improvement,» said Kira Zaslavskaya. Director for new products at Promomed Group.

The Expert Council, held in February 2022 and brought together reputable scientists and clinicians, noted in its resolution: «The data of international and Russian studies, as well as the accumulated international experience in the use of molnupiravir in the treatment of the novel coronavirus infection, allow us to consider it as one of the most potential drugs for the treatment of this infection.»